Privi Speciality Chemicals Limited — PPTs, 30-07-2026: Investor Presentation

Privi Speciality Chemicals reported a strong Q1 FY27 start. Total income grew 20.01% YoY to Rs 681.42 Cr. EBITDA jumped 18.73% YoY to Rs 167.47 Cr, while Net Profit soared 35.97% YoY to Rs 84.21 Cr. EPS for the quarter was Rs 21.56. ROCE improved to 21.70% (+299 bps YoY) and ROE to 22.72% (+112 bps YoY). Growth was broad-based across domestic and export markets, supported by diversified global presence and resilient operations.

Strategically, Privi aims for Rs 5,000 Cr revenue and Rs 1,000 Cr+ EBITDA by FY29-30, expecting over 20% EBITDA margins. Key drivers include expanding existing products, new innovations like Maltol, Ethyl Maltol, Furfural, and over 40 PRIGIV products. Merging Privi Fine Sciences and Privi Biotechnologies subsidiaries will boost core operations and agility, leveraging biotech R&D.

Recent highlights include new product launches set to expand market reach and capacity expansion projects on track for H2 2028. Flagship product augmentation is nearing completion. An export consignment fire resulted in a Rs 2.78 Cr loss, with an insurance claim filed.

Management sees a bright future with a strong balance sheet and clear roadmap, projecting sustained EBITDA margins above 20% from efficiency and product mix.